Thursday, 29 October 20269:59 am ISTIndia edition

Just in

9:20 amTelangana SIR: Form-6 rejections and Form-7 deletions unusually high during pre-SIR period
9:17 amRevenue authorities told to examine records in 13-year-old land dispute involving 70 acres of government land in Kalaburagi district
9:07 amHydroxyurea and transfusion together: a step forward in defining the value of combination therapy in severe sickle cell disease
9:06 amBeyond BRAF V600: emerging MAPK-targeted therapeutic strategies
9:05 amBeyond policy consensus: evidence reliability and editorial accountability in the age of artificial intelligence
SponsoredPut your announcement in this ticker from ₹69/day
9:04 amEndovascular thrombectomy for acute ischemic stroke with large infarct core: translating results from a randomized trial into clinical practice
9:01 amCyberabad Police plan one-way loop to ease IT corridor traffic
8:52 am‘Diwali gift’: Centre approves 3% DA hike for 4.8 million government employees
8:52 amU.S. warns allies to prepare for possible Iran strikes, retaliation after elections, say sources
8:45 amIIT Bombay forms panel to strengthen SC-ST cell following student's death
8:36 amUS-Japan's Joint Missiles Production Plan Against China's Aggression In Asia
8:35 am"When Will You Heal?" UAE President Plans Training With flydubai Captain Smit Machchhar
8:26 amDelhi Driver Stabbed Multiple Times For Asking For 'Extra Chole', Dies
8:23 amFiring Outside Delhi Businessman's House, Rohit Godara Gang Claims Attack
9:20 amTelangana SIR: Form-6 rejections and Form-7 deletions unusually high during pre-SIR period
9:17 amRevenue authorities told to examine records in 13-year-old land dispute involving 70 acres of government land in Kalaburagi district
9:07 amHydroxyurea and transfusion together: a step forward in defining the value of combination therapy in severe sickle cell disease
9:06 amBeyond BRAF V600: emerging MAPK-targeted therapeutic strategies
9:05 amBeyond policy consensus: evidence reliability and editorial accountability in the age of artificial intelligence
SponsoredPut your announcement in this ticker from ₹69/day
9:04 amEndovascular thrombectomy for acute ischemic stroke with large infarct core: translating results from a randomized trial into clinical practice
9:01 amCyberabad Police plan one-way loop to ease IT corridor traffic
8:52 am‘Diwali gift’: Centre approves 3% DA hike for 4.8 million government employees
8:52 amU.S. warns allies to prepare for possible Iran strikes, retaliation after elections, say sources
8:45 amIIT Bombay forms panel to strengthen SC-ST cell following student's death
8:36 amUS-Japan's Joint Missiles Production Plan Against China's Aggression In Asia
8:35 am"When Will You Heal?" UAE President Plans Training With flydubai Captain Smit Machchhar
8:26 amDelhi Driver Stabbed Multiple Times For Asking For 'Extra Chole', Dies
8:23 amFiring Outside Delhi Businessman's House, Rohit Godara Gang Claims Attack

India

TB Alliance fails to get patent for six-month treatment regimen

Reported by Hindustan Times 29 Oct 2026, 7:55 am IST 1 min read

Image: Hindustan Times. Rights remain with the publisher.

The Indian Patent Office on Tuesday rejected a patent application for BPaL, a combination of three medicines that has cut treatment for drug-resistant tuberculosis (TB) to six months, according to a joint statement by the groups that opposed it

Read the full report on Hindustan Times

Story file

Section: India
Topics: Health alerts
First reported by: Hindustan Times
Published: Thursday, 29 October 2026, 7:55 am IST
Coverage: One outlet so far

How this page works. The Headline Update lists this report from Hindustan Times with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.